Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Biomarker
C-reactive protein kinetics
Immune checkpoint inhibitors
Overall survival
Urothelial cancer
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
14
03
2020
accepted:
20
08
2020
pubmed:
3
9
2020
medline:
9
3
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
To assess the prognostic and predictive ability of early C-reactive protein (CRP) kinetics, dynamic changes in CRP levels, in patients with advanced urothelial cancer treated with pembrolizumab. We retrospectively evaluated 97 patients with advanced urothelial cancer treated with pembrolizumab in second-line or later settings. Patients were divided into three early CRP kinetics groups: non-elevated (baseline CRP < 5 mg/L), responder (baseline CRP ≥ 5 mg/L and CRP decreased below baseline at least once within 30 days), and non-responder (baseline CRP ≥ 5 mg/L and CRP never decreased to baseline within 30 days). Association between early CRP kinetics and pembrolizumab efficacy including objective response rate (ORR), disease control rate (DCR), and overall survival (OS) were evaluated. Based on early CRP kinetics, 40, 27, and 30 patients were classified as non-elevated, responder, and non-responder, respectively. ORR and DCR were 33% and 60% in non-elevated, 30% and 48% in responder, and 17% and 40% in non-responder; without a statistically significant difference. OS was significantly different among the non-elevated, responder, and non-responder groups (p < 0.01), with 1-year survival rates of 69%, 61%, and 31%, respectively. Early CRP kinetics could discriminate the OS of patients without objective response. Non-responder was an independent predictor for OS (HR 3.65, p < 0.01), as well as liver metastasis and ECOG PS ≥ 2. Early CRP kinetics is associated with survival of advanced urothelial cancer patients treated with pembrolizumab and could be a potential biomarker for clinical benefit from immune checkpoint inhibitors.
Identifiants
pubmed: 32876736
doi: 10.1007/s00262-020-02709-2
pii: 10.1007/s00262-020-02709-2
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers
0
C-Reactive Protein
9007-41-4
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-665Références
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683
doi: 10.1056/NEJMoa1613683
pubmed: 28212060
pmcid: 5635424
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA et al (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214. https://doi.org/10.1186/1479-5876-9-214
doi: 10.1186/1479-5876-9-214
pubmed: 22168571
pmcid: 3338100
Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US food and drug administration approvals. JAMA Inter Med 175(12):1992–1994. https://doi.org/10.1001/jamainternmed.2015.5868
doi: 10.1001/jamainternmed.2015.5868
Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543. https://doi.org/10.1200/jco.2015.61.6870
doi: 10.1200/jco.2015.61.6870
pubmed: 26261262
pmcid: 4622096
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34(13):1510–1517. https://doi.org/10.1200/jco.2015.64.0391
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/s1470-2045(17)30074-8
doi: 10.1016/s1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163. https://doi.org/10.2217/fon.09.136
doi: 10.2217/fon.09.136
pubmed: 20021215
Hilmy M, Bartlett JM, Underwood MA, McMillan DC (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92(4):625–627. https://doi.org/10.1038/sj.bjc.6602406
doi: 10.1038/sj.bjc.6602406
pubmed: 15726119
pmcid: 2361870
Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100(2):269–273. https://doi.org/10.1111/j.1464-410X.2007.06934.x
doi: 10.1111/j.1464-410X.2007.06934.x
pubmed: 17488302
Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H et al (2008) C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 101(8):978–981. https://doi.org/10.1111/j.1464-410X.2007.07408.x
doi: 10.1111/j.1464-410X.2007.07408.x
pubmed: 18190628
Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, Schwentner C et al (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 108(11):1800–1805. https://doi.org/10.1111/j.1464-410X.2011.10234.x
doi: 10.1111/j.1464-410X.2011.10234.x
pubmed: 21507193
Ishioka J, Saito K, Sakura M, Yokoyama M, Matsuoka Y, Numao N et al (2012) Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br J Cancer 107(7):1031–1036. https://doi.org/10.1038/bjc.2012.254
doi: 10.1038/bjc.2012.254
pubmed: 22918396
pmcid: 3461150
Morizane S, Iwamoto H, Yao A, Isoyama T, Sejima T, Takenaka A (2012) Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results. Cent European J Urol 65(2):62–66. https://doi.org/10.5173/ceju.2012.02.art1
doi: 10.5173/ceju.2012.02.art1
pubmed: 24578930
pmcid: 3921783
Eggers H, Seidel C, Schrader AJ, Lehmann R, Wegener G, Kuczyk MA et al (2013) Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 30(4):705. https://doi.org/10.1007/s12032-013-0705-6
doi: 10.1007/s12032-013-0705-6
pubmed: 24005810
Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A et al (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173(1):52–55. https://doi.org/10.1097/01.ju.0000146713.50673.e5
doi: 10.1097/01.ju.0000146713.50673.e5
pubmed: 15592024
Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY et al (1996) Predictors of clinical response to interleukin-2–based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 14(5):1697–1703. https://doi.org/10.1200/jco.1996.14.5.1697
doi: 10.1200/jco.1996.14.5.1697
pubmed: 8622090
Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT et al (2019) Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clin Exp Immunol 197(1):74–82. https://doi.org/10.1111/cei.13283
doi: 10.1111/cei.13283
pubmed: 30821848
pmcid: 6591141
Heppt MV, Heinzerling L, Kahler KC, Forschner A, Kirchberger MC, Loquai C et al (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer 82:56–65. https://doi.org/10.1016/j.ejca.2017.05.038
doi: 10.1016/j.ejca.2017.05.038
pubmed: 28648699
Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24(6):1697–1703. https://doi.org/10.1093/annonc/mdt027
doi: 10.1093/annonc/mdt027
pubmed: 23439861
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M et al (2014) Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63(7):675–683. https://doi.org/10.1007/s00262-014-1545-8
doi: 10.1007/s00262-014-1545-8
pubmed: 24695951
Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55(5):1145–1153. https://doi.org/10.1016/j.eururo.2008.10.012
doi: 10.1016/j.eururo.2008.10.012
pubmed: 18930583
Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S et al (2012) Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int 110(10):1478–1484. https://doi.org/10.1111/j.1464-410X.2012.11153.x
doi: 10.1111/j.1464-410X.2012.11153.x
pubmed: 22520732
Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M et al (2017) Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 22(6):1081–1086. https://doi.org/10.1007/s10147-017-1166-2
doi: 10.1007/s10147-017-1166-2
pubmed: 28733795
Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y et al (2020) C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol 25(1):135–144. https://doi.org/10.1007/s10147-019-01528-5
doi: 10.1007/s10147-019-01528-5
pubmed: 31512006
Ozawa Y, Amano Y, Kanata K, Hasegwa H, Matsui T, Kakutani T et al (2019) Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Med Oncol 36(4):33. https://doi.org/10.1007/s12032-019-1255-3
doi: 10.1007/s12032-019-1255-3
pubmed: 30825015
Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D et al (2020) Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors. J Urol [published online ahead of print, 2020 Jun 18] 101097JU0000000000001199. https://doi.org/10.1097/JU.0000000000001199
Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K et al (2019) Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol 145(10):2541–2546. https://doi.org/10.1007/s00432-019-02982-4
doi: 10.1007/s00432-019-02982-4
pubmed: 31367835
pmcid: 6751277
Powles T, Loriot Y, Gschwend JE, Bellmunt J, Geczi L, Vulsteke C et al (2018) KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer. Eur Urol Suppl 17:e1147–e1148. https://doi.org/10.1016/S1569-9056(18)31636-1
doi: 10.1016/S1569-9056(18)31636-1